| abstract |
The invention relates to a chemiluminescence quantitative detection kit for detecting intact PINP in serum. The kit is based on intact PINP in serum as a marker. Since the intact PINP metabolism in blood is not affected by kidney function, it can be truly and accurately It reflects the synthesis and bone formation of type 1 collagen, and adopts the double-antibody sandwich method, using acridine ester transient luminescence and magnetic bead separation technology, and using the cascade amplification effect of the biotin-avidin system. Compared with the performance of Roche PINP analysis products, it has a wider linear range (0.5‑1500ng/mL), a wide detection range, and With anti-interference, it can more effectively meet the requirements of clinical detection reagents. It can provide reliable clinical reference value for the early diagnosis, early intervention and prognosis of osteoporosis. |